查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1822447

2032 年神經病學個人化醫療市場預測：按治療類型、技術、應用、最終用戶和地區進行的全球分析

Personalized Medicine in Neurology Market Forecasts to 2032 - Global Analysis By Therapy Type (Pharmacogenomics, Digital Therapeutics, Biomarker-Based Diagnostics and Targeted Therapeutics), Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球神經病學個人化醫療市場預計在 2025 年達到 5,768 億美元，到 2032 年將達到 1,0211 億美元，預測期內的複合年成長率為 8.5%。

神經病學領域的精準醫療是一種以患者為中心的方法，根據個體獨特的基因、生物標記、環境和生活方式特徵，量身定做診斷、治療和預防策略。它突破了「一刀切」的模式，整合了基因組學、神經影像學和數據分析等先進技術，以從個體層面理解疾病機制。這種方法提高了癲癇、阿茲海默症和多發性硬化症等神經系統疾病的精準治療，改善了療效並最大限度地減少了副作用。個人化神經病學也有助於早期發現和標靶治療，使臨床醫生能夠根據每位患者的神經系統狀況，提供更有效、更可預測、更個人化的治療方案。

神經系統疾病盛行率上升

神經系統疾病的日益流行加速了個人化醫療的發展，使神經病學成為一個更精準、以病人為中心的領域。在日益成長的需求驅動下，研究人員正在利用基因、生物標記和生活方式數據，為阿茲海默症和帕金森氏症等疾病制定個人化治療方案。這種轉變正在推動診斷和治療領域的創新，使臨床醫生能夠提供更有效、更個人化的護理，最終改善數百萬神經系統疾病患者的治療效果和生活品質。

個人化醫療高成本

神經病學個人化醫療的高昂成本嚴重阻礙了治療的可及性和公平性。許多患者，尤其是資源匱乏地區的患者，無力負擔先進的基因組檢測和個人化醫療費用，導致治療結果有差異。這一經濟障礙減緩了個人化醫療的普及，限制了臨床試驗，並阻礙了可擴展解決方案的投資。最終，它損害了個人化醫療為所有人提供精準有效的神經系統治療的前景。

基因組學和分子診斷學的進展

基因組學和分子診斷技術的進步使得準確識別基因突變和生物標記物成為可能，徹底改變了神經病學領域的個人化醫療。這些創新使得癲癇、阿茲海默症和帕金森氏症等疾病的個人化治療成為可能，提高了療效並減少了副作用。早期診斷和風險預測增強了主動護理，而基因標靶治療則為以前無法治癒的疾病帶來了希望。這些進步共同推動著神經醫療保健向個人化、數據主導的轉型。

複雜的監管格局

複雜的監管環境嚴重阻礙了神經病學個人化醫療的發展。嚴格的核准流程、碎片化的全球標準以及對新興技術的緩慢適應，阻礙了創新和病患可及性。基因數據和生物標記方面的監管模糊性，進一步加劇了臨床整合的複雜性。這些障礙抑制了投資，阻礙了研究合作，限制了個人化治療方案，並最終阻礙了為最需要的患者提供精準有效的神經系統治療。

COVID-19的影響

COVID-19疫情凸顯了精準醫療和遠距離診斷的必要性，加速了神經學領域個人化醫療的應用。儘管醫療服務中斷，遠距遠端醫療、數位健康平台和基因組研究領域的技術創新仍推動了個人化神經病學治療的發展。然而，資源轉移和臨床試驗的延遲暫時阻礙了治療進展。整體而言，這場危機凸顯了個人化治療在神經系統疾病治療中的價值，並增強了醫療服務的韌性和適應性。

阿茲海默症預計將成為預測期內最大的細分市場

由於對更有效的個人化醫療的迫切需求，預計阿茲海默症領域將在預測期內佔據最大的市場佔有率。個人化醫療利用基因組學和生物標記來實現早期發現和個人化治療策略，這對於控制阿茲海默症的進展尤其重要。隨著研究投入的增加和技術的進步，該領域將受益於精準診斷和有針對性的干涉措施，從而顯著改善患者的治療效果，並減輕看護者和醫療保健系統的負擔。

預計微陣列領域在預測期內將實現最高複合年成長率

微陣列技術能夠同時分析數千個基因標記，預計在預測期內將達到最高成長率。該技術在識別疾病特異性生物標記物和根據個別神經系統特徵制定治療方案方面發揮關鍵作用。它在臨床環境中日益廣泛地應用於早期診斷和個人化醫療，這正在提升其市場潛力。隨著精準醫療需求的不斷成長，微陣列技術提供了一種可擴展且經濟高效的解決方案，以支援個人化神經病學應用的擴展。

比最大的地區

在預測期內，亞太地區預計將佔據最大的市場佔有率，這得益於其龐大的患者群體、不斷成長的醫療保健投入以及人們對神經系統疾病的認知不斷提高。中國、印度和日本等國家正迅速採用先進的診斷技術和個人化醫療方法。政府推動基因組研究和醫療保健數位化的舉措也進一步推動了市場成長。該地區不斷擴展的醫療保健基礎設施和日益成長的個人化醫療需求是全球神經病學個人化醫療格局的關鍵驅動力。

複合年成長率最高的地區：

預計北美地區在預測期內將實現最高的複合年成長率，這得益於其強大的科研基礎設施、高昂的醫療支出以及對創新技術的早期應用。該地區受益於學術機構、生物技術公司和醫療保健提供者之間的緊密合作，加速了基因組和分子診斷工具的開發。良好的法律規範以及阿茲海默症和多發性硬化症等神經系統疾病的盛行率不斷上升，進一步推動了個人化醫療的需求，使北美成為成長的領頭羊。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球神經病學個人化醫療市場（依治療類型）

  • 藥物基因組學
  • 數位治療學
  • 基於生物標記的診斷
  • 標靶治療藥物

6. 全球神經病學個人化醫療市場（按技術）

  • 次世代定序（NGS）
  • 基於CRISPR的診斷
  • 聚合酵素鏈鎖反應（PCR）
  • 微陣列
  • 其他技術

7. 全球神經病學個人化醫療市場（按應用）

  • 阿茲海默症
  • 多發性硬化症
  • 帕金森氏症
  • 癲癇
  • 中風
  • 其他用途

8. 全球神經病學個人化醫療市場（依最終用戶）

  • 醫院和診所
  • 研究機構
  • 診斷實驗室
  • 製藥和生物技術公司

9. 全球神經病學個人化醫療市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Roche Holding AG
  • Thermo Fisher Scientific Inc.
  • Novartis AG
  • Becton, Dickinson and Company（BD）
  • Biogen Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Siemens Healthineers
  • Pfizer Inc.
  • Abbott Laboratories
  • GlaxoSmithKline plc（GSK）
  • Eli Lilly and Company
  • Amgen Inc.
  • Illumina, Inc.
  • Neurocrine Biosciences, Inc.
  • QIAGEN NV
  • PerkinElmer, Inc.
  • Agilent Technologies, Inc.
Product Code: SMRC31202

According to Stratistics MRC, the Global Personalized Medicine in Neurology Market is accounted for $576.8 billion in 2025 and is expected to reach $1,021.1 billion by 2032 growing at a CAGR of 8.5% during the forecast period. Personalized medicine in neurology is a patient-centered approach that tailor's diagnosis, treatment, and prevention strategies to an individual's unique genetic, biomarker, environmental, and lifestyle profile. It moves beyond the "one-size-fits-all" model by integrating advanced technologies like genomics, neuroimaging, and data analytics to understand disease mechanisms at a personal level. This approach enhances precision in managing neurological disorders such as epilepsy, Alzheimer's disease, and multiple sclerosis, improving outcomes and minimizing side effects. Personalized neurology also fosters early detection and targeted therapies, empowering clinicians to deliver care that is more effective, predictive, and responsive to each patient's distinct neurological makeup.

Market Dynamics:

Driver:

Rising Prevalence of Neurological Disorders

The rising prevalence of neurological disorders is accelerating advancements in personalized medicine, transforming neurology into a more precise and patient-centric field. With increased demand, researchers are harnessing genetic, biomarker, and lifestyle data to tailor treatments for conditions like Alzheimer's and Parkinson's. This shift fosters innovation in diagnostics and therapeutics, empowering clinicians to deliver more effective, individualized care-ultimately improving outcomes and quality of life for millions affected by neurological diseases.

Restraint:

High Cost of Personalized Treatments

The high cost of personalized treatments in neurology significantly hinders accessibility and equity in care. Many patients, especially in low-resource settings, cannot afford advanced genomic testing or tailored therapies, leading to disparities in treatment outcomes. This financial barrier slows widespread adoption, limits clinical trials, and discourages investment in scalable solutions. Ultimately, it undermines the promise of personalized medicine to deliver precise, effective neurological care for all individuals.

Opportunity:

Advancements in Genomics and Molecular Diagnostics

Advancements in genomics and molecular diagnostics have revolutionized personalized medicine in neurology by enabling precise identification of genetic mutations and biomarkers. These innovations allow tailored treatments for conditions like epilepsy, Alzheimer's, and Parkinson's, improving efficacy and reducing side effects. Early diagnosis and risk prediction empower proactive care, while gene-targeted therapies offer hope for previously untreatable disorders. Together, they drive a transformative shift toward individualized, data-driven neurological healthcare.

Threat:

Complex Regulatory Landscape

The complex regulatory landscape significantly hampers the advancement of personalized medicine in neurology. Stringent approval processes, fragmented global standards, and slow adaptation to emerging technologies delay innovation and patient access. Regulatory ambiguity around genetic data and biomarkers further complicates clinical integration. These barriers discourage investment, stifle collaboration, and limit tailored treatment options, ultimately impeding progress in delivering precise, effective neurological care to patients who need it most.

Covid-19 Impact

The Covid-19 pandemic accelerated the adoption of personalized medicine in neurology by highlighting the need for precision care and remote diagnostics. It spurred innovation in telemedicine, digital health platforms, and genomic research, enabling tailored neurological treatments despite healthcare disruptions. However, resource diversion and delayed clinical trials temporarily hindered progress. Overall, the crisis underscored the value of individualized approaches in managing neurological conditions, fostering resilience and adaptability in care delivery.

The alzheimer's disease segment is expected to be the largest during the forecast period

The alzheimer's disease segment is expected to account for the largest market share during the forecast period, due to urgent need for more effective, individualized treatments. Personalized medicine enables early detection and tailored therapeutic strategies using genomics and biomarkers, which are especially critical in managing Alzheimer's progression. With increasing research investments and technological advancements, this segment benefits from precision diagnostics and targeted interventions, significantly improving patient outcomes and reducing the burden on caregivers and healthcare systems.

The microarray segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the microarray segment is predicted to witness the highest growth rate, due to its ability to analyze thousands of genetic markers simultaneously. This technology plays a pivotal role in identifying disease-specific biomarkers and tailoring treatments to individual neurological profiles. Its growing adoption in clinical settings for early diagnosis and personalized therapy selection enhances its market potential. As demand for precision medicine rises, microarrays offer scalable, cost-effective solutions that support the expansion of personalized neurology applications.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its vast patient population, increasing healthcare investments, and growing awareness of neurological disorders. Countries like China, India, and Japan are rapidly adopting advanced diagnostic technologies and personalized treatment approaches. Government initiatives promoting genomics research and healthcare digitization further fuel market growth. The region's expanding medical infrastructure and rising demand for tailored therapies make it a key driver in the global neurology personalization landscape.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust research infrastructure, high healthcare spending, and early adoption of innovative technologies. The region benefits from strong collaborations between academic institutions, biotech firms, and healthcare providers, accelerating the development of genomic and molecular diagnostic tools. Favorable regulatory frameworks and increasing prevalence of neurological disorders like Alzheimer's and multiple sclerosis further boost demand for personalized treatments, positioning North America as a growth leader.

Key players in the market

Some of the key players profiled in the Personalized Medicine in Neurology Market include Roche Holding AG, Thermo Fisher Scientific Inc., Novartis AG, Becton, Dickinson and Company (BD), Biogen Inc., Merck & Co., Inc., Johnson & Johnson, Siemens Healthineers, Pfizer Inc., Abbott Laboratories, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Illumina, Inc., Neurocrine Biosciences, Inc., QIAGEN N.V., PerkinElmer, Inc. and Agilent Technologies, Inc.

Key Developments:

In August 2025, Novartis has entered a collaboration with BioArctic to harness their BrainTransporter platform, aiming to develop novel neurological therapeutics. BioArctic will combine its BrainTransporter technology with a Novartis proprietary antibody to generate drug candidates.

In July 2025, Novartis has entered a collaboration with BioArctic to harness their BrainTransporter platform, aiming to develop novel neurological therapeutics. BioArctic will combine its BrainTransporter technology with a Novartis proprietary antibody to generate drug candidates.

Therapy Types Covered:

  • Pharmacogenomics
  • Digital Therapeutics
  • Biomarker-Based Diagnostics
  • Targeted Therapeutics

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • CRISPR-based Diagnostics
  • Polymerase Chain Reaction (PCR)
  • Microarray
  • Other Technologies

Applications Covered:

  • Alzheimer's Disease
  • Multiple Sclerosis
  • Parkinson's Disease
  • Epilepsy
  • Stroke
  • Other Neurological Disorders

End Users Covered:

  • Hospitals & Clinics
  • Research Institutes
  • Diagnostic Laboratories
  • Pharmaceutical & Biotechnology Companies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Personalized Medicine in Neurology Market, By Therapy Type

  • 5.1 Introduction
  • 5.2 Pharmacogenomics
  • 5.3 Digital Therapeutics
  • 5.4 Biomarker-Based Diagnostics
  • 5.5 Targeted Therapeutics

6 Global Personalized Medicine in Neurology Market, By Technology

  • 6.1 Introduction
  • 6.2 Next-Generation Sequencing (NGS)
  • 6.3 CRISPR-based Diagnostics
  • 6.4 Polymerase Chain Reaction (PCR)
  • 6.5 Microarray
  • 6.6 Other Technologies

7 Global Personalized Medicine in Neurology Market, By Application

  • 7.1 Introduction
  • 7.2 Alzheimer's Disease
  • 7.3 Multiple Sclerosis
  • 7.4 Parkinson's Disease
  • 7.5 Epilepsy
  • 7.6 Stroke
  • 7.7 Other Neurological Disorders

8 Global Personalized Medicine in Neurology Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Research Institutes
  • 8.4 Diagnostic Laboratories
  • 8.5 Pharmaceutical & Biotechnology Companies

9 Global Personalized Medicine in Neurology Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Roche Holding AG
  • 11.2 Thermo Fisher Scientific Inc.
  • 11.3 Novartis AG
  • 11.4 Becton, Dickinson and Company (BD)
  • 11.5 Biogen Inc.
  • 11.6 Merck & Co., Inc.
  • 11.7 Johnson & Johnson
  • 11.8 Siemens Healthineers
  • 11.9 Pfizer Inc.
  • 11.10 Abbott Laboratories
  • 11.11 GlaxoSmithKline plc (GSK)
  • 11.12 Eli Lilly and Company
  • 11.13 Amgen Inc.
  • 11.14 Illumina, Inc.
  • 11.15 Neurocrine Biosciences, Inc.
  • 11.16 QIAGEN N.V.
  • 11.17 PerkinElmer, Inc.
  • 11.18 Agilent Technologies, Inc.

List of Tables

  • Table 1 Global Personalized Medicine in Neurology Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 3 Global Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
  • Table 4 Global Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 5 Global Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
  • Table 6 Global Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
  • Table 7 Global Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 8 Global Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 9 Global Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
  • Table 10 Global Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 11 Global Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 12 Global Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 13 Global Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
  • Table 14 Global Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 15 Global Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 16 Global Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 17 Global Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 18 Global Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
  • Table 19 Global Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
  • Table 20 Global Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
  • Table 21 Global Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 22 Global Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 23 Global Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 24 Global Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 25 North America Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
  • Table 26 North America Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 27 North America Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
  • Table 28 North America Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 29 North America Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
  • Table 30 North America Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
  • Table 31 North America Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 32 North America Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 33 North America Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
  • Table 34 North America Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 35 North America Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 36 North America Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 37 North America Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
  • Table 38 North America Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 39 North America Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 40 North America Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 41 North America Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 42 North America Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
  • Table 43 North America Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
  • Table 44 North America Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
  • Table 45 North America Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 46 North America Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 47 North America Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 48 North America Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 49 Europe Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
  • Table 50 Europe Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 51 Europe Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
  • Table 52 Europe Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 53 Europe Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
  • Table 54 Europe Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
  • Table 55 Europe Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 56 Europe Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 57 Europe Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
  • Table 58 Europe Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 59 Europe Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 60 Europe Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 61 Europe Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
  • Table 62 Europe Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 63 Europe Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 64 Europe Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 65 Europe Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 66 Europe Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
  • Table 67 Europe Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
  • Table 68 Europe Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
  • Table 69 Europe Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 70 Europe Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 71 Europe Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 72 Europe Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 73 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
  • Table 74 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 75 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
  • Table 76 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 77 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
  • Table 78 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
  • Table 79 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 80 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 81 Asia Pacific Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
  • Table 82 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 83 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 84 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 85 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
  • Table 86 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 87 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 88 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 89 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 90 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
  • Table 91 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
  • Table 92 Asia Pacific Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
  • Table 93 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 94 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 95 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 96 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 97 South America Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
  • Table 98 South America Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 99 South America Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
  • Table 100 South America Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 101 South America Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
  • Table 102 South America Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
  • Table 103 South America Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 104 South America Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 105 South America Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
  • Table 106 South America Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 107 South America Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 108 South America Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 109 South America Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
  • Table 110 South America Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 111 South America Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 112 South America Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 113 South America Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 114 South America Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
  • Table 115 South America Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
  • Table 116 South America Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
  • Table 117 South America Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 118 South America Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 119 South America Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 120 South America Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 121 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
  • Table 122 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 123 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
  • Table 124 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 125 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
  • Table 126 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
  • Table 127 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 128 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 129 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
  • Table 130 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 131 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 132 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 133 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
  • Table 134 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 135 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 136 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 137 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 138 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
  • Table 139 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
  • Table 140 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
  • Table 141 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 142 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 143 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 144 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)